コンピュータ支援による創薬市場：タイプ、治療分野、エンドユーザー別-2025-2030年の世界予測

コンピュータ支援による創薬市場の2023年の市場規模は37億4,000万米ドルで、2024年には40億8,000万米ドルに達すると予測され、CAGR 9.71％で成長し、2030年には71億6,000万米ドルに達すると予測されています。

コンピュータ支援による創薬（CADD）には、新規医薬化合物の発見と最適化のプロセスを支援する計算手法とツールの使用が含まれます。この革新的なアプローチは、従来の医薬品開発に関連する時間とコストを削減するために不可欠であり、効率化を目指す製薬企業にとって重要な必需品となっています。CADDは、ターゲットの同定やバリデーションからリード化合物の最適化や前臨床試験まで、医薬品開発の様々な段階を通じて適用されます。最終用途の範囲は、主に製薬・バイオテクノロジー企業、学術・研究機関、CRO（医薬品開発業務受託機関）に及びます。市場は、慢性疾患の有病率の増加、精密医療の重視の高まり、AIおよび機械学習技術の採用の高まりなどの要因によって牽引されています。この分野のビジネスチャンスには、創薬プロセスの精度とスピードを高める、より洗練されたアルゴリズムとプラットフォームの開発が含まれます。企業は、AI駆動型プラットフォームへの投資、ビッグデータ分析の統合、学術機関やハイテク企業との協力関係の拡大により、こうした進歩を活用することができます。しかし、初期コストの高さ、データプライバシーへの懸念、高品質なデータソースの必要性などの課題が、成長の妨げとなる可能性があります。また、規制上のハードルや、正確なモデリングの妨げとなりうる生物学的システムの複雑さといった限界もあります。同市場は技術の進歩に伴い継続的に進化しているため、企業はバーチャルスクリーニング、分子モデリング、データ統合などの分野における技術革新に注力することが極めて重要です。市場の性質に関する考察によると、既存のリーダーと革新的な新規参入者の両方が存在する強力な競合情勢であることが示唆されます。市場シェアを獲得するための最良の戦略には、技術的進歩を活用し、戦略的パートナーシップを結び、個別化医療アプローチをサポートする患者特異的モデルの開発を重視することが含まれ、最終的には精密治療へ向かう業界の動向と一致します。

市場力学：急速に進化するコンピュータ支援による創薬市場の主要市場インサイトを公開

コンピュータ支援による創薬市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 製薬・バイオ医薬品企業による医薬品開発活動への注目の高まり
  • 前臨床試験中に生成される膨大なデータを管理する必要性の高まり
• 市場抑制要因
  • コンピュータ支援による創薬ソリューションの導入コストの高さ
• 市場機会
  • コンピュータ支援による創薬ソリューションにおける技術統合の増加
  • 革新的技術の採用に対する政府の支援政策
• 市場の課題
  • コンピュータ支援による創薬ソリューションに関連する幅広い代替技術の利用可能性

ポーターのファイブフォース：コンピュータ支援による創薬市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、コンピュータ支援による創薬市場の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：コンピュータ支援による創薬市場における外部からの影響の把握

外部マクロ環境要因は、コンピュータ支援による創薬市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析コンピュータ支援による創薬市場における競合情勢の把握

コンピュータ支援による創薬市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックスコンピュータ支援による創薬市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、コンピュータ支援による創薬市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨コンピュータ支援による創薬市場における成功への道筋を描く

コンピュータ支援による創薬市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 製薬企業やバイオ医薬品企業による医薬品開発活動への注目の高まり
    • 前臨床研究中に生成される大量のデータを管理する必要性が高まっている
  • 抑制要因
    • コンピュータ支援による創薬ソリューションの実装コストが高い
  • 機会
    • コンピュータ支援による創薬ソリューションにおけるテクノロジーの統合の増加
    • 革新的技術の導入を支援する政府の政策
  • 課題
    • コンピュータ支援による創薬ソリューションに関連する幅広い代替技術の利用可能性
• 市場セグメンテーション分析
  • タイプ：新しい化合物の活性を予測できるモデルを開発するためのリガンドベースの薬物設計の使用の増加
  • エンドユーザー：生物学的プロセスを理解し、潜在的な新薬を特定するコンピュータ支援による創薬の高い可能性
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 コンピュータ支援別創薬市場：タイプ別

• リガンドベースの医薬品設計
• シーケンスベースのアプローチ
• 構造に基づく医薬品設計

第7章 コンピュータ支援別創薬市場治療領域別

• 心血管疾患
• 糖尿病
• 神経学
• 腫瘍学
• 呼吸器疾患

第8章 コンピュータ支援別創薬市場：エンドユーザー別

• バイオテクノロジー企業
• 製薬会社
• 調査室

第9章 南北アメリカのコンピュータ支援別創薬市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域のコンピュータ支援別創薬市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカのコンピュータ支援別創薬市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
  • ミリポアシグマ、AIDDISONを発表：効率的な医薬品開発のための先駆的なSaaSプラットフォーム
  • バイエルAGとGoogle Cloudが量子化学による新薬発見の推進で提携
• 戦略分析と提言

企業一覧

• AbbVie Inc.
• Accelrys, Inc.
• AstraZeneca PLC
• Bayer AG
• Bio-Rad Laboratories, Inc.
• Boehringer Ingelheim International GmbH
• Chemical Computing Group Inc.
• Dassault Systemes SE
• Eli Lilly and Company
• Gilead Sciences, Inc.
• GlaxoSmithKline PLC
• Merck & Co., Inc.
• Novartis AG
• Pfizer Inc.
• Regeneron Pharmaceuticals, Inc.
• Roche Holding AG
• Sanofi S.A.
• Schrodinger, Inc.
• Simulations Plus, Inc.
• Vertex Pharmaceuticals Incorporated

LIST OF FIGURES

• FIGURE 1. COMPUTER-AIDED DRUG DISCOVERY MARKET RESEARCH PROCESS
• FIGURE 2. COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. COMPUTER-AIDED DRUG DISCOVERY MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. COMPUTER-AIDED DRUG DISCOVERY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. COMPUTER-AIDED DRUG DISCOVERY MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. COMPUTER-AIDED DRUG DISCOVERY MARKET DYNAMICS
• TABLE 7. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY LIGAND-BASED DRUG DESIGN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SEQUENCE-BASED APPROACHES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY STRUCTURE-BASED DRUG DESIGN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY CARDIOVASCULAR DISEASE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY DIABETES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY RESPIRATORY DISEASE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. AMERICAS COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 22. AMERICAS COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 23. AMERICAS COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 24. AMERICAS COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 25. ARGENTINA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 26. ARGENTINA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 27. ARGENTINA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 28. BRAZIL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 29. BRAZIL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 30. BRAZIL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 31. CANADA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 32. CANADA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 33. CANADA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 34. MEXICO COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 35. MEXICO COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 36. MEXICO COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 37. UNITED STATES COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 38. UNITED STATES COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 39. UNITED STATES COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 40. UNITED STATES COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 41. ASIA-PACIFIC COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 42. ASIA-PACIFIC COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 43. ASIA-PACIFIC COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 44. ASIA-PACIFIC COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 45. AUSTRALIA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 46. AUSTRALIA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 47. AUSTRALIA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 48. CHINA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 49. CHINA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 50. CHINA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 51. INDIA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 52. INDIA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 53. INDIA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 54. INDONESIA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 55. INDONESIA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 56. INDONESIA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 57. JAPAN COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 58. JAPAN COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 59. JAPAN COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 60. MALAYSIA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 61. MALAYSIA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 62. MALAYSIA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 63. PHILIPPINES COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 64. PHILIPPINES COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 65. PHILIPPINES COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 66. SINGAPORE COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 67. SINGAPORE COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 68. SINGAPORE COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 69. SOUTH KOREA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 70. SOUTH KOREA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 71. SOUTH KOREA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 72. TAIWAN COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 73. TAIWAN COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 74. TAIWAN COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 75. THAILAND COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 76. THAILAND COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 77. THAILAND COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 78. VIETNAM COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 79. VIETNAM COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 80. VIETNAM COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 81. EUROPE, MIDDLE EAST & AFRICA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 82. EUROPE, MIDDLE EAST & AFRICA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 83. EUROPE, MIDDLE EAST & AFRICA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 84. EUROPE, MIDDLE EAST & AFRICA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 85. DENMARK COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 86. DENMARK COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 87. DENMARK COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 88. EGYPT COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 89. EGYPT COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 90. EGYPT COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 91. FINLAND COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 92. FINLAND COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 93. FINLAND COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 94. FRANCE COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 95. FRANCE COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 96. FRANCE COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 97. GERMANY COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 98. GERMANY COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 99. GERMANY COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 100. ISRAEL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 101. ISRAEL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 102. ISRAEL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 103. ITALY COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 104. ITALY COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 105. ITALY COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 106. NETHERLANDS COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 107. NETHERLANDS COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 108. NETHERLANDS COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 109. NIGERIA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 110. NIGERIA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 111. NIGERIA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 112. NORWAY COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 113. NORWAY COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 114. NORWAY COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 115. POLAND COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 116. POLAND COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 117. POLAND COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 118. QATAR COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 119. QATAR COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 120. QATAR COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 121. RUSSIA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 122. RUSSIA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 123. RUSSIA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 124. SAUDI ARABIA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 125. SAUDI ARABIA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 126. SAUDI ARABIA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 127. SOUTH AFRICA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 128. SOUTH AFRICA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 129. SOUTH AFRICA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 130. SPAIN COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 131. SPAIN COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 132. SPAIN COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 133. SWEDEN COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 134. SWEDEN COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 135. SWEDEN COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 136. SWITZERLAND COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 137. SWITZERLAND COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 138. SWITZERLAND COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 139. TURKEY COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 140. TURKEY COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 141. TURKEY COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 142. UNITED ARAB EMIRATES COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 143. UNITED ARAB EMIRATES COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 144. UNITED ARAB EMIRATES COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 145. UNITED KINGDOM COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 146. UNITED KINGDOM COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 147. UNITED KINGDOM COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 148. COMPUTER-AIDED DRUG DISCOVERY MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 149. COMPUTER-AIDED DRUG DISCOVERY MARKET, FPNV POSITIONING MATRIX, 2023

The Computer-aided Drug Discovery Market was valued at USD 3.74 billion in 2023, expected to reach USD 4.08 billion in 2024, and is projected to grow at a CAGR of 9.71%, to USD 7.16 billion by 2030.

Computer-aided Drug Discovery (CADD) involves the use of computational methods and tools to aid in the process of discovering and optimizing new pharmaceutical compounds. This innovative approach is essential in reducing the time and cost associated with traditional drug development, making it a significant necessity for pharmaceutical companies striving for efficiency. CADD is applied throughout various stages of drug development, from target identification and validation to lead optimization and preclinical testing. The end-use scope primarily spans pharmaceutical and biotechnology companies, academic and research institutions, and contract research organizations (CROs). The market is driven by factors such as the increasing prevalence of chronic diseases, a growing emphasis on precision medicine, and the rising adoption of AI and machine learning technologies. Opportunities in this field include the development of more sophisticated algorithms and platforms that enhance the accuracy and speed of drug discovery processes. Companies can capitalize on these advancements by investing in AI-driven platforms, integrating big data analytics, and expanding collaborations with academic institutions and tech firms. However, challenges such as high initial costs, data privacy concerns, and the need for high-quality data sources can hinder growth. Limitations also include regulatory hurdles and the complexity of biological systems that may impede accurate modeling. The market is continuously evolving with technological advancements, making it crucial for businesses to focus on innovation in areas like virtual screening, molecular modeling, and data integration. Insights into the market's nature suggest a strong competitive landscape with both established leaders and innovative newcomers. The best strategies for capturing market share involve leveraging technological advancements, forging strategic partnerships, and emphasizing the development of patient-specific models to support personalized medicine approaches, ultimately aligning with the industry's trend towards precision therapeutics.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Computer-aided Drug Discovery Market

The Computer-aided Drug Discovery Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising focus on drug development activities by pharmaceutical and biopharmaceutical companies
  • Increasing need to manage the large data generated during preclinical studies
• Market Restraints
  • High cost of implementation of computer-aided drug discovery solutions
• Market Opportunities
  • Rising integration of technologies in computer-aided drug discovery solutions
  • Supportive government policies for the adoption of innovative technologies
• Market Challenges
  • Availability of wide alternative technologies associated with computer-aided drug discovery solutions

Porter's Five Forces: A Strategic Tool for Navigating the Computer-aided Drug Discovery Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Computer-aided Drug Discovery Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Computer-aided Drug Discovery Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Computer-aided Drug Discovery Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Computer-aided Drug Discovery Market

A detailed market share analysis in the Computer-aided Drug Discovery Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Computer-aided Drug Discovery Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Computer-aided Drug Discovery Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Computer-aided Drug Discovery Market

A strategic analysis of the Computer-aided Drug Discovery Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Computer-aided Drug Discovery Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Accelrys, Inc., AstraZeneca PLC, Bayer AG, Bio-Rad Laboratories, Inc., Boehringer Ingelheim International GmbH, Chemical Computing Group Inc., Dassault Systemes SE, Eli Lilly and Company, Gilead Sciences, Inc., GlaxoSmithKline PLC, Merck & Co., Inc., Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Roche Holding AG, Sanofi S.A., Schrodinger, Inc., Simulations Plus, Inc., and Vertex Pharmaceuticals Incorporated.

Market Segmentation & Coverage

This research report categorizes the Computer-aided Drug Discovery Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Type, market is studied across Ligand-Based Drug Design, Sequence-Based Approaches, and Structure-Based Drug Design.
• Based on Therapeutic Area, market is studied across Cardiovascular Disease, Diabetes, Neurology, Oncology, and Respiratory Disease.
• Based on End User, market is studied across Biotechnology Companies, Pharmaceutical Companies, and Research Laboratories.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising focus on drug development activities by pharmaceutical and biopharmaceutical companies
    • 5.1.1.2. Increasing need to manage the large data generated during preclinical studies
  • 5.1.2. Restraints
    • 5.1.2.1. High cost of implementation of computer-aided drug discovery solutions
  • 5.1.3. Opportunities
    • 5.1.3.1. Rising integration of technologies in computer-aided drug discovery solutions
    • 5.1.3.2. Supportive government policies for the adoption of innovative technologies
  • 5.1.4. Challenges
    • 5.1.4.1. Availability of wide alternative technologies associated with computer-aided drug discovery solutions
• 5.2. Market Segmentation Analysis
  • 5.2.1. Type: Growing usage of ligand-based drug design to develop a model that can predict the activity of new compounds
  • 5.2.2. End User: High potential of computer-aided drug discovery to understand biological processes and identify potential new drugs
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Computer-aided Drug Discovery Market, by Type

• 6.1. Introduction
• 6.2. Ligand-Based Drug Design
• 6.3. Sequence-Based Approaches
• 6.4. Structure-Based Drug Design

7. Computer-aided Drug Discovery Market, by Therapeutic Area

• 7.1. Introduction
• 7.2. Cardiovascular Disease
• 7.3. Diabetes
• 7.4. Neurology
• 7.5. Oncology
• 7.6. Respiratory Disease

8. Computer-aided Drug Discovery Market, by End User

• 8.1. Introduction
• 8.2. Biotechnology Companies
• 8.3. Pharmaceutical Companies
• 8.4. Research Laboratories

9. Americas Computer-aided Drug Discovery Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Computer-aided Drug Discovery Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Computer-aided Drug Discovery Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
  • 12.3.1. MilliporeSigma Introduces AIDDISON: A Pioneering SaaS Platform for Streamlined Drug Development
  • 12.3.2. Bayer AG and Google Cloud Partner to Advance Drug Discovery Through Quantum Chemistry
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. AbbVie Inc.
• 2. Accelrys, Inc.
• 3. AstraZeneca PLC
• 4. Bayer AG
• 5. Bio-Rad Laboratories, Inc.
• 6. Boehringer Ingelheim International GmbH
• 7. Chemical Computing Group Inc.
• 8. Dassault Systemes SE
• 9. Eli Lilly and Company
• 10. Gilead Sciences, Inc.
• 11. GlaxoSmithKline PLC
• 12. Merck & Co., Inc.
• 13. Novartis AG
• 14. Pfizer Inc.
• 15. Regeneron Pharmaceuticals, Inc.
• 16. Roche Holding AG
• 17. Sanofi S.A.
• 18. Schrodinger, Inc.
• 19. Simulations Plus, Inc.
• 20. Vertex Pharmaceuticals Incorporated